Delpharm

Events

On 2 April, Delpharm finalized the acquisition of the Meppel pharmaceutical manufacturing facility, from Astellas in the Netherlands.
The acquisition of this site, fully equipped with state-of-the-art technologies, will be an additional asset to the production of solid dosage forms. With FDA certification, Delpharm has strengthened its position as a supplier to the US market.

A leading CDMO

Drug developer and Contract manufacturer. With its plants network, Delpharm is in the Top 5 CDMOs Worldwide.

Dosage forms

Delpharm produces most dosage forms; non-sterile and sterile liquids, solids, semi-solids and biotech.

Development & Regulation

A team of experts to support new pharmaceutical products.

100

Management ownership 100%

1

Turnover billion €

5

World Top 5

6000

Headcount

News

Delpharm continues its growth in Europe with the acquisition of state-of-the-art drug production facilities in the Netherlands, from Astellas.

World-leading CDMO Delpharm expands its pharmaceutical network with the acquisition from Astellas of the Meppel pharmaceutical manufacturing facility.

Prefilled syringes

With Delpharm Leiden development center and Tours experts, we can support you in the development and manufacture of prefilled syringes. We have the capacity to produce between 25 and 30 million syringes a year in sizes ranging from 1ml to 50ml.